Redeye gives its view on last weeks events in Calliditas. We mainly focus on last week’s acquisition, as well as the upcoming top-line data of the pivotal phase III trial with Nefecon in IgA Nephropathy. We expect data to be published early November and see good prospects for momentum in the share over the coming months, ahead of presentation of the data.